ACADIA Pharmaceuticals Inc. (ACAD)

NMS – Цена в реальном времени. Валюта: USD

29.45

+0.04 (0.14%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

29.40

-0.05 (-0.17%)

После закрытия: Aug 12, 2026, 4:41 PM EDT

12.08.2026

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.

07.08.2026

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

06.08.2026

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

06.08.2026

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

05.08.2026

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

05.08.2026

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

04.08.2026

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.

ACADIA Pharmaceuticals Inc. (ACAD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Видео

No Data

Пресс-релизы

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Search stocks

ACADIA Pharmaceuticals Inc. (ACAD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Видео

No Data

Пресс-релизы

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results